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Abstract
Considering the limitations of the current leishmaniases chemotherapy and the lack of 
effective vaccines, the identification of novel drugs and/or vaccine approaches for the 
leishmaniases treatment and control is urgently required. In fact, a rational strategy for 
the parasite control can be based on the identification of essential metabolic pathways 
of the parasite. One of the most important pathways is the polyamine biosynthesis. 
Leishmania is auxotrophic for many amino acids, such as l-arginine, a precursor of orni-
thine, putrescine, and spermidine. These metabolites are essential for parasite replication 
and establishment of infection in the mammalian host. In addition, Leishmania has a spe-
cific and complex machinery to uptake and metabolize exogenous sources of those mol-
ecules. In this chapter, we will focus on the main aspects of the polyamine pathway as a 
potential target for infection control aiming for new targets for Leishmania chemotherapy.
Keywords: amastigote, l-arginine metabolism, putrescine, ornithine, spermidine, 
spermine, amino acid permease 3, amino acid transport, nitric oxide, nitric oxide 
synthase, glycosome
1. Introduction
Leishmaniases are diseases characterized by cutaneous, mucocutaneous, diffuse, or visceral 
clinical manifestations [1]. They are currently endemic in 98 countries and territories world-
wide, with estimated 700,000 to 1 million new cases and 20,000–30,000 deaths occurring annu-
ally [2]. The incidence of this disease is mainly in underdeveloped countries within South East 
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Asia, East Africa, and Latin America; however, it is also endemic in several Mediterranean 
countries leading to highlight the importance of transmission in travelers [3]. Leishmania-HIV 
co-infection has emerged as an opportunistic infection and has been described as important 
clinical, diagnostic, and epidemiological implications [4]. The virus and the parasite compro-
mise the immune response, leading to the replication of both and consequent progression of 
Leishmania infection [5].
Leishmaniases are caused by the protozoan parasites of Leishmania genus. The parasite pres-
ents two main morphological forms during its life cycle. The promastigote, an extracellular 
long and flagellated form, proliferates in the digestive tract of the invertebrate host, and the 
amastigote, an obligate intracellular form with a nonapparent flagellum, proliferates in the 
phagolysosome of the mammalian host macrophage [1, 6]. These two distinct host environ-
ments submit the parasite to a rapid adaptation in gene/protein expression, cellular signaling, 
metabolism, and morphology to survival during promastigote-to-amastigote differentiation 
[7–11]. In fact, the parasite can sense temperature, pH, and nutrient availability, controlling 
the amino acid and purine transport and osmoregulation to establish the infection [12].
The immune response in Leishmania infection is mediated by phagocytic cells such as neutro-
phils, macrophages, and dendritic cells. The monocyte recruitment and macrophage differ-
entiation result in the recognition of the parasite, its phagocytosis, and consequent induction 
of inflammatory response with nitric oxide (NO) production through nitric oxide synthase 
2 (NOS2) and reactive oxygen species production [13–16]. These actions coordinate the 
innate immune response and can promote the parasite killing, as showed for L. amazonensis, 
L. major, and L. donovani [17]. On the other hand, Leishmania is able to escape from these 
defense mechanisms leading to amastigote differentiation and proliferation in the macro-
phage phagolysosome [18]. Therefore, the antibodies have little or negligible effect in the 
infection. These coordinate mechanisms of evasion can be mediated by Leishmania polyamine 
pathway through induction of parasite-arginase (L-ARG) activity to produce polyamines [12, 
19–22]. It is interesting to note that l-arginine is the common substrate for NOS2 and arginase 
1 (ARG1). Both enzymes are competitively regulated by cytokines from T helper 1 (Th1), 
such as interferon gamma (IFN-γ), or T helper 2 (Th2), as interleukins IL-4, IL-13, and TGF-
β, inducing the macrophages M1 or M2 polarization, respectively [23–27]. M2 macrophages 
contribute to susceptibility in cutaneous leishmaniasis [28].
The preconized treatment for leishmaniases is the use of antimonials, the same treatment used 
since its description by Gaspar Vianna in 1912 [6]. First, the recommendation was based on 
the use of trivalent antimonial; however, it was replaced with pentavalent antimonial, more 
efficient, and less toxic [29]. The pentavalent antimonial formulations are represented by 
meglumine antimoniate and sodium stibogluconate and still considered as the main line for 
leishmaniases treatment today [30]. These compounds have side effects, the treatment is long, 
and they are administered through intramuscular injections or intravenous infusions, requir-
ing the patient hospitalization [30]. The high toxicity of these compounds can be due to the 
high concentration used in the current treatment (about four times higher than 20 years ago) 
and to the acquired resistance by the parasite as a result of long exposure of the drug and inad-
equate dosages [30]. An alternative line of treatment can be based on the use of amphotericin 
and its liposomal derivatives; however, they also present side effects, which restrict its use 
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besides the high cost of the treatment [30]. Pentamidine has the mechanism of action based on 
the inhibition of polyamine synthesis [31, 32] and can also be used for unresponsive antimonial 
treatment [33]. Miltefosine, which is administrated as an oral drug, is a promisor alternative 
for leishmaniases treatment [34] with high effective and tolerated rate in visceral leishmaniasis 
in India [35] and later also effective for cutaneous leishmaniasis [36–38]. However, miltefosine-
unresponsive cases have been reported in regions outside India [36]. Paromomycin is another 
promising treatment for visceral leishmaniasis control in India, and it has been described as 
effective in monotherapy as well as in combination with other drugs [39]. Azole antifungal 
agents, like ketoconazole, have been also used in the leishmaniases treatment for decades [40], 
and its mechanism of action is based on the inhibition of ergosterol biosynthesis [41].
The current leishmaniases chemotherapy, as represented in Figure 1, is based on these seven 
compounds, which present different origins of discovery, unique structures, and distinct 
modes of action [42].
Figure 1. Chemical structure of the current antileishmanial drugs: amphotericin, meglumine antimoniate, miltefosine, 
paromomycin, ketoconazole, sodium stibogluconate, and pentamidine.
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To date, there is no single effective treatment for leishmaniases. In fact, the leishmaniases 
treatment is complicated due to the complexity of the different species of Leishmania and 
their interaction with the host cells. The available therapies show high toxicity, low efficacy, 
long duration of treatment, high costs, and increased rate of resistant parasites. Then, there 
is an emergency and challenge in the development of new drugs for leishmaniases chemo-
therapy. The emergency is due to the increased incidence of case reports, and the challenge 
is based on the leishmaniasis classification as a neglected tropical disease. The high incidence 
in underdeveloped regions of the world implicates a lack of interest in research development 
and minimum financial funding from pharmaceutical industries. There are many studies 
describing potential targets for vaccine approaches; however, no licensed vaccine is available 
for human treatment.
A rational strategy for the parasite control can be developed based on the identification of fun-
damental metabolic pathways of both the parasite and the host, such as polyamine biosynthe-
sis. Polyamines are involved in chromatin structure and DNA replication. They interact with 
both DNA and RNA, promoting gene expression regulation and transport mechanisms [43].
In this review, we will point aspects of the current treatment, relevant targets and highlight 
the potential for polyamine pathway for leishmaniases chemotherapy because it is essential 
for parasite replication and survival.
2. The current chemotherapy
The leishmaniases chemotherapy was discovered in an empiric way, which means all drugs 
used are re-purposed from other therapeutic prescriptions. In fact, this scenario is far to be 
optimal for a disease whose incidence is increasing in the endemic areas.
Then, we will review the current leishmaniases chemotherapy with description of the drugs 
and its mechanism of action.
2.1. Pentavalent antimonials
Pentavalent antimonials are represented by the formulations meglumine antimoniate and 
sodium stibogluconate (Figure 1) and consist in the most frequently used drug for leishmani-
ases treatment because they are effective for both visceral and cutaneous leishmaniases [30]. 
Both formulations present poor oral absorption, leading to an intramuscular or intravenous 
administration [44]. Besides its accumulation in the tissues, antimonials can cause severe car-
diotoxicity, pancreatitis, and nephrotoxicity effects, requiring hospitalization and close moni-
toring of patients [45, 46]. In addition to these side effects, the long period of treatment leads 
to noncompliance and abandonment, favoring the emergence of resistant parasites and the 
drug efficacy varying from region to region compromising its use [33].
The antimonial mechanism of action involves the depletion of intracellular ATP due to inter-
ference in glycolysis and fatty acids β oxidation [47]. There are some studies evidencing that 
antimony kills the parasite by a process of apoptosis involving DNA fragmentation and exter-
nalization of phosphatidylserine on the membrane surface [48].
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2.2. Pentamidine
Pentamidine is an aromatic diamidine (Figure 1) used mainly in the treatment of cutaneous 
leishmaniasis unresponsive to pentavalent antimonial treatment [33]. Most regimens are based 
on intramuscular injections or intravenous infusions per day for about 30 days [49]. However, 
due to its toxicity and rapidly emerging resistance, pentamidine was abandoned in India in 1990 
and replaced by amphotericin B, as the recommended treatment [50]. In contrast, pentamidine 
is the first line of choice for treatment in French Guiana, where it is the only available drug [51].
The pentamidine mechanism of action is related to inhibition of the polyamine synthesis [31, 32], 
activity of S-adenosyl-l-methionine decarboxylase [52], the alteration of the membrane flu-
idity, lipid metabolism, mitochondrial activity [53], the calcium transport [54], disintegra-
tion of the kinetoplast and mitochondria, and collapse of the mitochondrial membrane [55]. 
Pentamidine binds to DNA essentially in AT-rich regions, such as the kDNA, affecting the 
transcription and replication process [53]. Additionally, L. amazonensis and L. donovani para-
sites treated with pentamidine showed decrease in arginine, ornithine, and putrescine pools, 
while the levels of spermidine remain intact [31]. In L. donovani, pentamidine is described as a 
competitive inhibitor in the arginine uptake [56] and a noncompetitive inhibitor of putrescine 
and spermidine transport in L. infantum [57], L. donovani, and L. mexicana [58]. In fact, pent-
amidine uses polyamine transporters to enter in the parasite leading to an altered polyamine 
uptake in pentamidine-resistant Leishmania [31, 59].
2.3. Amphotericin B
Amphotericin B (Figure 1) and its lipid formulation have been considered as the most striking 
advances for visceral leishmaniasis treatment [60, 61]. This antifungal antibiotic has also been 
considered as the first-line drug for treatment due to its high efficacy against antimonial-unre-
sponsive cases [62]. Amphotericin B is administrated through intravenous infusion and can 
present side effects, such as nephrotoxicity and myocarditis, leading to close monitoring and 
hospitalization for 4–5 weeks [63]. The advent of liposome technology allows minimization 
of dose-limiting toxicity, providing highly effective and safe therapy. The ambisome formula-
tion is probably the most efficient of all currently available drugs for leishmaniases treatment, 
and it has been used as the first-line drug for treatment worldwide [64, 65].
The mechanism of action of amphotericin B is based on the sterols metabolism. It interferes in 
the ergosterol biosynthesis of the cell membrane of Leishmania, causing changes in the mem-
brane permeability and leakage of intracellular components that damage the cell, triggering 
parasite killing [66].
2.4. Miltefosine
Miltefosine (Figure 1) was the first effective oral agent for visceral leishmaniasis treatment. 
This drug was originally used for cancer treatment, but it showed high efficacy for leishmani-
ases unresponsive to antimonial treatment [67]. Since it has been described effective for leish-
maniases treatment, it has been used worldwide, however, with a variable rate of efficacy [37, 
38, 68]. Drug-resistant cases have been reported, and increasing relapse rates can be due to the 
reflection of its long half-life in case of inadequate use [69].
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Miltefosine interferes with cell membrane composition by inhibiting phospholipid metabo-
lism with reduction of phosphatidylcholine content and enhancement of phosphatidyleth-
anolamine content in the membrane of L. donovani [70]. Resistance to miltefosine is easily 
selected in vitro [71, 72]. The resistance mechanisms can be due to drug pressure inducing the 
mechanisms of regulation in Leishmania lipid metabolism by a defect in drug internalization 
mediated by miltefosine transporter machinery [69, 70, 72].
2.5. Paromomycin
Paromomycin is an aminoglycoside antibiotic (Figure 1) used to treat bacterial infections and 
requires metabolic energy from electron transport chain across plasmatic membrane [73, 74]. 
Paromomycin has shown high cure rate in leishmaniases treatment in India [75]. When orally 
administered, paromomycin is poorly absorbed, limiting its use to intramuscular injections.
The mechanism of paromomycin action in Leishmania is not precisely known, but protein 
synthesis has been proposed as target, based on studies with bacteria. Other possible mecha-
nisms had been proposed, including alteration of membrane fluidity and effects on the mito-
chondria membrane potential. The ribosomal complex, responsible for translating the genetic 
information from mRNA to protein, is the usual site of action for aminoglycoside antibiot-
ics. Based on paromomycin-resistant L. donovani, the upregulation of ribosomal proteins was 
observed in the resistant parasite, suggesting that protein synthesis machinery is the site of 
action in Leishmania [76, 77]. Transcriptomic profile of paromomycin-resistant L. donovani 
shows decreased protein synthesis and degradation and the role in oxidative phosphoryla-
tion, glycosomal succinate fermentation, DNA synthesis and repair, and also alteration in the 
NO production during macrophage infection [78].
2.6. Ketoconazole
Ketoconazole is an oral antifungal drug (Figure 1) that inhibits ergosterol biosynthesis. 
Ergosterol is the major sterol in Leishmania, and it is a potential target of some drugs because 
it is absent in mammalian cells, in which cholesterol is the main sterol. The mechanism of 
action of ketoconazole causes the accumulation of methyl sterols due to changes in membrane 
permeability [41]. Ketoconazole treatment of murine macrophage infected with L. mexicana 
altered the levels of free sterols in amastigotes [41]. Oral ketoconazole treatment resulted in 
failure in the control of L. braziliensis cutaneous lesions or ulcers [79, 80]. On the other hand, 
some studies have shown efficacy in controlling L. braziliensis cutaneous lesions [40] and 
L. amazonensis murine infection in vitro and in vivo [81]. Ketoconazole associated with anti-
mony presented toxicity to amastigote forms of L. amazonensis [82].
3. Biological targets for therapy
In the course of the Leishmania life cycle, environmental changes inside the invertebrate and mam-
malian host represent important external signals for gene expression regulation. These signals 
start with the starvation of nutrients, such as amino acids, signaling for metacyclogenesis during 
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the transformation from promastigote procyclic forms into promastigote metacyclic forms. In this 
step, procyclic forms are adhered to epithelia of insect midgut, and the starvation promotes their 
release and starts the differentiation to infective metacyclic forms accompanied with their migra-
tion to the insect proboscis. From this site, the metacyclic forms are regurgitated during a new 
blood meal [83]. The following signal is the temperature shift from the invertebrate host (25°C) to 
the mammalian host (37°C), representing a challenge for parasite survival and differentiation into 
amastigote forms. The heat-shock proteins are examples of gene activation that allows parasite 
survival in rapid temperature changes [10, 84, 85]. The pH change, from 7.0 to 5.5, is the last sig-
nal, due to the phagosome and lysosome fusion to form the phagolysosome inside the phagocytic 
cells, where the amastigotes replicate [9–11].
Despite these environmental changes, promastigotes and amastigotes have common meta-
bolic features that distinguish them from their hosts and can be used as new antiparasitic 
targets. New potential drug targets have been described along the years, and we will describe 
here some of them, such as protein kinases, glycolate enzyme, purine pathway, and polyamine 
pathway. Additionally, besides considering the future of leishmaniases treatment, encom-
passing new methodological approaches available today, the study of metabolic pathways 
allows the understanding of the biology and physiology of the parasite. Recent approaches, 
such as “omics”, have been provided new insights into fundamental pathways of the parasite 
and/or in the Leishmania-host interactions that can be explored as potential new targets.
3.1. Protein kinases
The protein kinases are involved in several essential biological processes, including metab-
olism, gene expression, cell proliferation, motility, differentiation, and death [86]. Protein 
kinases act on serine, threonine, tyrosine, or histidine residues of proteins leading to phos-
phorylation. Phosphorylation can modify the function of a protein in a variety of ways, such 
as protein activity, stabilization, or degradation. The localization within a particular compart-
ment of a cell can initiate or disrupt its interaction with other proteins [87]. These kinases 
along with phosphatases play a major role in protein and enzyme regulation. Leishmania-
activated kinases play an important role in parasite thermo-tolerance and virulence [88].
These enzymes have been explored as therapeutic target by pharmaceutical industry, with a 
focus on the discovery of non-ATP-competitive kinase inhibitors, directing these modulators 
to target sites that can regulate specific protein kinases [89, 90].
3.2. Glycolytic enzymes
The glycolytic enzymes of trypanosomes are attractive drug targets because the glycolysis 
is essential for energy requirements. The ATP synthesis through glycolytic enzymes starts 
with glucose to produce glycerol and pyruvate, maintaining the ATP and NAD balance of 
glycosome compartment. The glycolytic enzymes, localized in glycosome and cytosol, have 
emerged as drug targets in parasitic diseases [76, 91]. Targeting the glycosomal enzymes 
could alter the production of energy and NADH by glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) and its oxidization through mitochondrial glycerol-3-phosphate oxidase to 
shift the electrons [91].
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The inhibition of energy production in Leishmania can be based on the use of adenosine ana-
logs, blocking the binding of NAD+ to GAPDH [92–95]. Some analogs have been described as 
inhibitor of Leishmania growth due the block of energy production.
3.3. Purine metabolism
Another interesting pathway to explore as new targets for leishmaniases chemotherapy is the 
purine metabolism. Leishmania and other protozoa are unable to synthesize purine nucleo-
tides de novo and must uptake them from the host [96]. The parasite uptake of preformed 
purine host is mediated by nucleoside transporters [97].
Purine nucleotides and their derivatives are precursors of vast cellular and metabolic pro-
cesses, including energy production, cell signaling, synthesis of nucleic acids, modulation of 
enzymatic activities, and synthesis of co-enzymes [96, 97]. This unique characteristic may be 
the basis for susceptibility of Leishmania to purine analogs [97, 98]. Purine analogs have been 
described for use in the parasite control, such as tubercidin (TUB) [98–100]. TUB is effective 
against promastigotes from L. amazonensis, L. braziliensis, L. infantum chagasi, and L. major [98, 
101]. The same antiparasitic efficacy is described for amastigotes from L. amazonensis when 
associated with a specific and selective inhibitor of nucleoside transport for mammalian cells, 
the nitrobenzylthioinosine (NMBPR) [98]. The selectivity of TUB-NBMPR combined treat-
ment for Leishmania produces highly selective toxicity against the parasite, inhibition of mam-
malian nucleoside transporter, supporting the hypothesis that these transporters are different 
between the parasite and its host [98].
In addition, based on tubercidin-resistant L. major parasites, the upregulation of the tuber-
cidin-resistant protein, an endoplasmic reticulum protein is observed in these resistant line, 
suggesting that protein synthesis machinery is the site of action of TUB in Leishmania [99].
3.4. Polyamine pathway
The polyamine pathway is important for parasite replication and to the establishment of 
infection in the host [102]. Fundamental differences in this pathway are described between the 
parasite and its host, pointing to antileishmanial chemotherapy targets (Figure 2). Polyamines 
(putrescine, spermidine, and spermine) are essential substrates in all cells, including parasitic 
protozoa. Their intracellular concentration may be regulated at the level of their biosynthesis, 
interconversion, degradation, and transport [103]. In Leishmania, the hydrolysis of l-arginine 
by L-ARG to produce ornithine and urea is a crucial initial step for polyamines production 
[12, 102, 104–106] and for parasite growth and survival in promastigote and amastigote forms 
[107–110]. Thus, an inhibition of polyamine synthesis represents a promisor target for leish-
maniases chemotherapy (Figure 2).
The polyamines biosynthetic pathway is characterized by the decarboxylation of the amino 
acid ornithine to putrescine and catalyzed by ornithine decarboxylase (ODC), a key enzyme on 
this pathway. Putrescine is then converted into spermidine by the action of a spermidine syn-
thase (SpdS). Finally, spermidine is used to form both spermine by spermine synthase (SpmS) 
and trypanothione through trypanothione synthase (TryS). Trypanothione is an important 
regulator of intracellular thiol redox balance [111, 112]. Leishmania also uses l-arginine to 
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produce NO and citrulline by enzyme NOS-like activity [113–115]. The controversial NO pro-
duction by the parasite is still not completely understood because NO is the same molecule 
produced by host macrophages to promote the parasite’s killing [105, 109, 116]. However, 
NO production has been related to metacyclogenesis signaling in promastigote forms and 
to amastigote replication of L. amazonensis in a dependent way to the l-arginine availability 
and L-ARG activity [7]. The participation of a NOS-like enzyme in this pathway was recently 
described based on in silico analysis of oxidoreductase family domains [7]. Besides this, previ-
ous metabolome evidences of NO and citrulline production also indicated the activity of the 
enzyme in L. amazonensis [115]. Although this enzyme is not completely characterized, NOS-
like enzyme could also be a potential drug target (Figure 2), as an inhibitor of NO production 
decreasing amastigote differentiation and replication.
Once L-arginine is not synthesized de novo, the parasite developed molecular mechanisms 
to sense the amino acid availability and activity of enzymes involved in polyamines produc-
tion [115–120]. L-ARG is an enzyme with regulatory roles, as the modulation of l-arginine 
Figure 2. Schematic representation of polyamine-related chemotherapeutic approaches for Leishmania, such as the (1) 
inhibition of amino acid permease 3 (AAP3) in both plasmatic membrane and glycosome, preventing the l-arginine 
uptake; (2) inhibition of polyamines synthesis by arginase (ARG), ornithine decarboxylase (ODC), S-adenosylmethionine 
decarboxylase (AdoMetDC), spermidine synthase (SpdS), spermine synthase (SpmS), and trypanothione synthase 
(TryS); (3) inhibition of polyamines, preventing the parasite replication; and (4) inhibition of the parasite nitric oxide 
synthase (NOS-like), preventing the nitric oxide (NO) production and amastigote differentiation and replication. (?) 
predicted but not confirmed cytosolic localization, (N) nucleus, (K) kinetoplast, and (G) glycosome.
The Polyamine Pathway as a Potential Target for Leishmaniases Chemotherapy
http://dx.doi.org/10.5772/intechopen.75867
115
availability with consequently regulation of polyamine synthesis [121]. L-ARG presents a gly-
cosomal import signal, the three amino acids SKL [122, 123]. Glycosomes are peroxisome-like 
organelles, essential to parasite survival, likely due to compartmentalization of key metabolic 
enzymes [124]. Glycosomes are not only involved in glycolysis but are also predicted to carry out 
gluconeogenesis, reaction of the hexose-monophosphate pathway, purine salvage and pyrimi-
dine biosynthesis, fatty acids β-oxidation, fatty acids elongation, and biosynthesis of other lip-
ids. In addition, they seem to have involved in oxidant stress protection [123]. Another role for 
the existence of glycosome in kinetoplastid organisms can be related with the importance of 
sequestering metabolic pathways into this compartmentalized organelle and then facilitated the 
parasite development because the turnover of pathways (or part of them) is more rapidly and 
efficiently upon induction when they are compartmentalized than when present in the cytosol 
as individual enzymes [124].
Besides the glycosomal signal, L-ARG was demonstrated in fact localized in the glycosome 
compartment of L. mexicana and L. amazonensis promastigotes [102, 104, 122]. In addition, this 
glycosomal localization is maintained in intracellular amastigotes in macrophage infections 
[102]. Interestingly, the glycosomal localization is crucial for its activity because the mislo-
calization of the enzyme reduced in vitro and in vivo infectivity [102]. RNA-seq data revealed 
that L-ARG expression is downregulated in L. amazonensis axenic amastigotes when com-
pared to promastigotes [8]. In contrast, an upregulation is observed in Leishmania intracellular 
amastigotes from BALB/c macrophages infection [12]. Altogether, these data reinforce the 
existence of a differential modulation of the enzyme activity under different environment 
conditions [8].
Leishmania amino acid uptake can also be considered for new antileishmanial target (Figure 2). 
l-Arginine uptake in macrophages is mediated by cationic amino acids (CAT1, CAT2A, 
CAT2B, and CAT3) [125]. A reduction in CAT2B expression and l-arginine uptake by treat-
ment with melatonin, hormone of dark signal to biological rhythm, impairs in vitro L. ama-
zonensis infectivity in murine model [126]. In contrast, Leishmania has a complex and specific 
machinery to uptake this amino acid. l-Arginine uptake is mediated by amino acid permease 
3 (AAP3) in L. donovani and L. amazonensis [116, 119, 120]. Furthermore, the AAP3 dual local-
ization in the plasma membrane and in the glycosome from promastigotes and axenic amasti-
gotes of L. amazonensis and L. donovani [102, 118, 119] can be an indicative that the inhibition of 
l-arginine trafficking through the plasma membrane and/or through the glycosome suggests 
a promisor target for leishmaniases chemotherapy (Figure 2) [116, 119].
The drugs targeting enzymes involved in the polyamines production could reduce the parasite 
growth and survival. The 3-aminooxy-1-aminopropane (APA) and L-α-difluoromethylornithine 
(DFMO) are ODC inhibitors. APA is an isosteric analog of putrescine and inhibits the growth 
of L. donovani promastigotes and amastigotes [127]. However, DFMO presents a controversial 
data as a leishmanicidal compound. DFMO is described successful against African sleeping 
sickness [128], and it is also efficient in inhibition of L. donovani, L. infantum, and L. guyanensis 
infections but not for L. major and L. mexicana [129, 130]. Furthermore, other studies described 
DFMO inefficacy against Leishmania [131]. The basis for the selectivity toxicity of DFMO in 
the parasite is complex. The ODC from the parasite is no less susceptible to inhibition by 
DFMO than ODC from the host. However, many metabolic differences between parasites and 
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mammals have been identified, such as the inability of the parasite to obtain exogenous poly-
amines, the synthesis of trypanothione that could interfere in the susceptibility to DFMO [132] 
and its metabolic stability. ODC has a long half-life (more than 6 h), unlike the host protein 
(less than 30 min), which can be the basis for susceptibility of DFMO in the parasite [133].
A 5′-((Z)-4-amino-2-butenyl)methylamino)-5′-deoxyadenosine (MDL73811) can also be used 
as an inhibitor of adenosyl methionine decarboxylase (AdometDC), enzyme that forms 
decarboxylate S-adenosyl methionine. This molecule can be used with putrescine by SpdS 
to produce spermidine and with spermidine to produce spermine [58, 102, 121, 134–137], as 
described for L. donovani [137].
In addition, the importance of polyamine pathway has been described with the generation 
of L. donovani, L. major, L. mexicana, and L. amazonensis null mutants of essential enzymes 
involved in this pathway, such as ARG, ODC, AdoMetDC, or SpdS. Knockout parasites of 
these enzymes have been providing data of how these parasites synthesize polyamines and 
depend on supplementation of products of these enzymes for survival [7, 8, 102, 105, 106, 138]. 
The role of polyamine pathway in intracellular amastigotes is controversial; in vitro and in 
vivo infections with L. amazonensis arginase knockout parasites present lower infection index 
[102, 119]. In contrast, in vivo infection with L. donovani arginase knockout parasites reduces 
the parasite burden in the liver of mice but does not impact the parasite burden in the spleen 
[106]. Supplementation with putrescine recovered the levels of infectivity of L. amazonensis in 
murine macrophages with reduced levels of l-arginine transport [126]. A comparison of the 
polyamine pathway in these two different species reveals a variation in the polyamine pool 
within the phagolysosome, and consequently difference in the polyamine uptake by the para-
site may contribute to differences in virulence [138].
3.5. “Omics”
The application of “omics” approaches in Leishmania research has been providing new 
insights into the biological processes that drive the replication and differentiation steps of the 
parasite. They can also provide insights into drug transport and metabolism. Furthermore, 
these approaches have been revealing as a fundamental tool for the biology, the discovery of 
new targets for chemotherapy, and the determination of drug-resistance mechanisms [139]. 
The progress of Leishmania spp. genome annotations has been providing a lot of information, 
including a review of previous genome annotations data and its misassembling, in an attempt 
to improve the current genome and gene annotations [8, 140, 141]. Since genomes are charac-
terized by a high degree of synteny among the species, the genomic annotations can explain 
the specificity for tissues tropisms, differential immune responses, variations in drug suscep-
tibility, gene content, and gene expression regulation, among the species.
Leishmania exhibit many unique features in their biology, and the elucidation of the molecular 
basis of them may lead to the development of new strategies for the control of the disease. 
Leishmania parasite genome is organized as large cluster of genes in the 5′–3′ direction on the 
DNA strand. The polycistronic transcription occurs in an initiation site, forming a primary 
RNA transcript across the chromosome. The maturation of mRNA, as well as its abundance, 
occurs by post-transcriptional mechanisms [142, 143].
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Based on that, the following approaches can be helpful for the future chemotherapy targets 
discovery. The genomic studies allow the identification of single-nucleotide polymorphisms 
(SNPs), copy number variations (CNVs), genomic rearrangements, and genomic annotations, 
using whole genome sequencing and exome techniques. The knowledge of biological targets 
can point to the selectivity of the drug and the use of known validated targets allowing a 
better understanding of their biological mechanisms. Gazanion et al. demonstrated by next-
generation sequencing an unprecedented number of drug-resistance/target genes against all 
drugs currently used in leishmaniases chemotherapy [139]. This screening method can be 
useful to discover the drug targets and to understand the resistance mechanisms [139].
The transcriptomic studies have been extensively used allowing the discovery of mRNA sta-
bility, mRNA processing, and gene expression regulation, through microarrays or RNA-seq 
techniques [7, 8, 119]. Previous studies revealed sequence elements that control the abun-
dance of mRNAs by influencing their maturation and stability. These changes in transcripts 
abundance during the life cycle of the parasite may lead to the identification of essential 
genes and thus pointing them as potential candidates for vaccine or drug targets [144]. A 
previous study demonstrated that the differentiation of promastigotes to amastigotes from 
L. amazonensis leads to a modulation of genes involved in the polyamine biosynthesis [8]. 
Furthermore, the absence of arginase activity in promastigotes of L. amazonensis leads to a 
differential level of metabolites from this pathway: citrulline, l-arginine, and l-glutamate 
increase levels, whereas aspartate, proline, ornithine, and putrescine decrease levels [8]. 
These findings reveal the importance of L-ARG in parasite survival and differentiation and 
indicate the existence of a coordinate response in the absence of L-ARG activity in the poly-
amine pathway.
The proteomic studies allow the discovery of cellular components, protein expression, post-
translation modification, and protein interaction, using quantitative proteomics by two-
dimensional gel electrophoresis (2DE), liquid chromatography mass spectrometry (LC-MS), 
or stable isotope labeling by amino acids in cell culture (SILAC). Post-translation modifica-
tions are of particular interest in Leishmania because the parasite regulates gene expression 
at post-transcriptional and post-translational levels [143]. The metabolomic studies allow 
the discovery of metabolite signatures through MS or nuclear magnetic resonance spectros-
copy (NMR) methodologies. This approach can be used to evaluate how specific metabolites 
respond under different environmental or physiological conditions, providing interesting 
data about the mode of action and resistance mechanisms of drugs in parasitic protozoa [145]. 
The metabolome fingerprints obtained with L. amazonensis in the absence of L-ARG activity 
and/or under amino acids starvation demonstrated how Leishmania is able to use an alterna-
tive route to provide substrates for the polyamine pathway [115]. In addition, metabolome 
fingerprints of L. infantum resistant to antimonials showed metabolite profile modification in 
Leishmania pathways, corresponding mainly to amino acids or their alternative metabolites in 
the polyamine pathways with the thiol-dependent redox metabolism [146].
4. Concluding remarks
In the absence of effective vaccine and vector control, the eradication of leishmaniases is 
mostly dependent on chemotherapy. Besides other vials, such as the protein kinases, glycolytic 
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enzymes, and purine metabolism, studies involving the polyamine pathway have been increas-
ing over the years due to its consideration as a promisor target for leishmaniases chemotherapy. 
The importance of this pathway for Leishmania replication is unquestionable, and the polyamine 
pathway exhibits significant differences compared to its host pathway. Leishmania amastigotes 
reside in the phagolysosome of host macrophage, but the ability to uptake polyamines may 
vary depending on the Leishmania species and/or the type of host macrophage. Then, the focus 
on the polyamine pathway as chemotherapeutic approaches, such as inhibition of polyamine 
transport, inhibition of l-arginine transport, inhibition of polyamine synthesis, inhibition of 
polyamine interconversion, or inhibition of NOS-like enzyme, may be considered in the future 
of leishmaniases chemotherapy.
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